Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
| ▸ | FEN1 | P39748 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487602 | 0.90 | BRD4 (0.56) | BRD4HTR6CAMKK2 | |
| SCHEMBL8325104 | 0.87 | BRD4 (0.60) | BRD4MAOBHTR6DRD2HTR2A | |
| SCHEMBL13745805 | 0.84 | BRD4 (0.41) | BRD4ALOX5APFEN1MAOBHTR6 | |
| SCHEMBL13746241 | 0.83 | BRD4 (0.54) | BRD4FEN1HTR6METCYP2C19 | |
| SCHEMBL8324896 | 0.81 | BRD4 (0.60) | BRD4FEN1HTR6DRD2HTR2A | |
| SCHEMBL1799967 | 0.80 | BRD4 (0.67) | BRD4HTR6METCYP2C19 | |
| SCHEMBL13745655 | 0.79 | BRD4 (0.58) | BRD4FEN1HTR6 | |
| SCHEMBL1487576 | 0.78 | HTR6 (0.45) | BRD4HTR6CAMKK2 | |
| SCHEMBL8325105 | 0.78 | BRD4 (0.57) | BRD4HTR6DRD2HTR2AHTR7 | |
| SCHEMBL13746307 | 0.78 | BRD4 (0.61) | BRD4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1339/4885ALOX5AP 2122/4885FEN1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.